



MEDICAL NUTRITION USA, INC.

NASDAQ: MDNU
www.mdnu.com



Overview —

Medical Nutrition USA, Inc. develops and distributes unique, highly effective, concentrated, liquid nutritional supplements and medical foods.

The majority of the company’s sales are to nursing homes, hospitals and dialysis clinics. The Company’s products are clinically proven to meet the needs of the large and growing population of nutritionally at risk elderly people, many of whom lack the appetite and metabolic health to properly meet their nutritional needs through conventional diets.

Medical Nutrition’s products are primarily concentrated liquid formulations that are highly bio-available, easy to consume, and require far smaller serving sizes than conventional supplements. An example is the Company’s Pro-Stat® product line, wherein a one ounce serving provides the same amount of protein as 24-ounces of conventional reconstituted powder.


Delivering the same or greater benefit in less volume combined with additional specific therapeutic advantages is descriptive of the Company’s entire product offering, which addresses:

- Protein Energy Malnutrition (PEM) in a variety of indications and conditions (Pro-Stat);
- Chronic irregularity (Fiber-Stat®); and
- Urinary tract infections (UTI-Stat®).

Clinically Proven —

A mainstay of Medical Nutrition’s marketing strategy is a significant and growing body of independent clinical trials that demonstrate product safety and efficacy.

These trials, combined with the company’s own research and product development, play a key role in Medical Nutrition’s success in penetrating markets and gaining share against much larger competitors.



Financial Information, thousands (except EPS)			
Fiscal Year End: January 31			
	FY 2008	FY 2009	Q1 2010
Revenue	\$12,800	\$13,700	\$3,400
EBIT	\$2,100	(\$700)	(\$188)
Net Income	\$870	(\$490)	(\$140)
Diluted EPS	\$0.06	(\$0.04)	(\$0.01)

Growth strategy —

Management is focused on building market share and growing revenue within well-defined, institutional markets that generate the bulk of the Company’s sales to date.

In the past 12 months, the Company has expanded its sales force, implemented more aggressive pricing and expanded its distribution network. Moreover, the Company expands its market opportunity and reinforces its reputation as a leading innovator in with the development and introduction of a significant new product approximately every 10-12 months.

This strategy has propelled steady gains in Medical Nutrition’s branded unit sales and net revenues, accounting for a 23% compounded annual growth in revenues over the past five years.

Why invest in MDNU —

- Strong revenue growth potential associated with a focused growth strategy and a large untapped market opportunity.
- Proven capability and success in penetrating markets and identifying, developing and introducing successful new products.
- Compelling market demographic trends (e.g., a rapidly aging adult population in North America) that support increased product sales and create opportunities to grow share in an expanding market.
- Rigorous, independent clinical studies demonstrate product effectiveness and efficacy.
- Strong balance sheet; positive cash flows; no debt.



MEDICAL NUTRITION USA, INC.

Company Contact:

Frank J. Kimmerling, CFO
 Medical Nutrition USA, Inc.
 10 West Forest Avenue
 Englewood, NJ 07631
 1-800-221-0308
 fkimmerling@mnidirect.net

Investor Relations Contact:

Adam Friedman
 Adam Friedman Associates
 11 East 44th Street, 5th Floor
 New York, NY 10017
 212-981-2529 ext. 18
 adam@adam-friedman.com



Management Team —

**Frank A. Newman,
 Chairman & CEO**

- Chairman, President and CEO Eckerd Corporation (NYSE). From IPO in August 1993 to its sale to J.C. Penney in March 1997, Eckerd's shareholder value increased 500%.
- President and CEO of F&M Distributors (NASDAQ), a drug store chain he took public in 1992.
- EVP Retail – Household Merchandising (Household Finance).

**Frank J. Kimmerling,
 VP/Finance, CFO**

- CFO, Lamina Lighting, a global manufacturing company focused on LED technology.
- Senior manager and CFO, Geller & Co.'s Emerging Business Group, a finance and accounting services provider focused on high-growth companies in the venture-backed and small-public-company spaces.
- Divisional CFO, BISYS Group Inc., a large, publicly held financial services provider.

**Arnold Gans,
 Chief Scientific Officer**

- President of Control Drug, Inc., a private manufacturer of nutritional protein supplements to medical clinics and institutions.
- In 1976 developed clinical and maintenance studies for Dexatrim and original Slim Fast formula for Thomson Medical Company.
- Designed product and clinical protocol studies for SmoQuits, a smoking cessation product marketed by Amway Corp.

**Robert Mathias,
 VP Sales & Marketing**

- Vice President, Marketing & Business Development, Alimentary Health Ltd.
- Director of Marketing, Novartis Medical Nutrition
- Director, Adult Nutrition, Mead Johnson Nutritionals

Product Overview —

Pro-Stat® is a concentrated, enzymatically hydrolyzed, liquid protein that is rich in high nitrogen-donor amino acids. In Pro-Stat's hydrolyzed form, the large protein molecules have been broken down (predigested) into free amino acids and polypeptides for increased absorption and assimilation, leading to rapid onset of action. Rich in arginine, glycine, proline and hydroxyproline, Pro-Stat® has been proven effective in treating protein energy malnutrition, aiding tissue regeneration, stimulating pressure ulcer healing and protein anabolism. Pro-Stat® is certified Kosher, available in a variety of flavors and in the following formulations for specific disease states:

Pro-Stat® 64 – carbohydrate free, is an ideal formula for diabetics. Per serving, Pro-Stat® 64 has 15 grams of protein and 72 K/cal per 30 ml (one ounce).

Pro-Stat® 101 – enhanced calorie, provides the highest concentration of protein and calories per ounce. Per serving, Pro-Stat® 101 has 15 grams of protein and 101 k/cal per 30 ml (one ounce).

Pro-Stat® RC – renal care formula combines added B vitamins, zinc and FOS* (for intestinal health) specifically for hemodialysis patients. B vitamin benefits are manifold, and are needed for enhanced circulation and blood formation, antibody production and cell growth, as well as the metabolism of fat, protein and carbohydrates.

Pro-Stat® Profile™ – formulated for those whose dietary intake is limited in essential amino acids and require extra protein. Pro-Stat® Profile™ provides a concentrated source of complete protein and energy with the IOM 2005 essential amino acid pattern (PDCAAS=100%).

Pro-Stat® AWC – advanced wound care formula includes added elemental zinc, arginine, cystine, citrulline and vitamin C to accelerate wound healing, build muscle, repair tissue, increase blood flow to wounds and fight infection.



Fiber-Stat® with FOS* delivers 15 grams of natural soluble fiber per 2 tablespoons (30 ml) for gentle and reliable bowel regulation and intestinal health. Fiber-Stat's natural ingredients help fulfill the RDA for dietary fiber, stimulate water and electrolyte uptake in the colon and the growth of beneficial bacteria.

UTI-Stat™ with Proantinox® is a natural urinary tract cleansing complex containing a proprietary blend of concentrated cranberry proanthocyanidins, ascorbic acid, D-mannose, FOS and bromelain to inhibit adhesion of infection causing E-coli bacteria to urinary tract walls and help prevent recurrence of infection.



* Prebiotic fructo-oligosaccharides.